Literature DB >> 31302706

The entirely subcutaneous ICDTM system in patients with congenital heart disease: experience from a large single-centre analysis.

Kevin Willy1, Florian Reinke1, Nils Bögeholz1, Julia Köbe1, Lars Eckardt1, Gerrit Frommeyer1.   

Abstract

AIMS: The subcutaneous implantable cardioverter-defibrillator (S-ICDTM) is an important advance in device therapy for the prevention of sudden cardiac death (SCD). Although current guidelines recommend S-ICDTM use, long-term data are still limited, especially in subgroups such as adult patients with congenital heart diseases. This cohort is of high interest because of the difficult anatomic conditions in these patients. METHODS AND
RESULTS: All S-ICDTM patients with an underlying congenital heart disease (CHD) resulting in an indication for ICD implantation (n = 20 patients) in our large-scaled single-centre S-ICDTM registry (n = 249 patients) were included in this study. Baseline characteristics, appropriate and inappropriate shocks, and complications were documented in a mean follow-up of 36 months. Primary prevention of SCD was the indication for implantation of an S-ICDTM in six patients (30%). Of all 20 patients with an overall mean age of 40.5 ± 11.5 years, 12 were male (60%). The mean left ventricular ejection fraction was 46.5 ± 11.3%. Nine episodes of ventricular tachycardia (two monomorphic and seven polymorphic) were adequately terminated in three patients (15%). In two patients, T-Wave-Oversensing resulting in an inappropriate shock was observed, which could be managed by changing the sensing vector or activation of the SMART PASSTM filter. There were no S-ICDTM system-related infections. In one patient, surgical revision was necessary due to a persistent haematoma.
CONCLUSION: The S-ICDTM seems to be a valuable option for the prevention of SCD in patients with various CHDs and complex anatomical anomalies. The S-ICDTM is safe and works effectively, also in these complex patients. Inadequate shock delivery was rare and could be managed by reprogramming. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Congenital heart disease; S-ICD; Sudden cardiac death

Year:  2019        PMID: 31302706     DOI: 10.1093/europace/euz190

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  5 in total

1.  Eligibility for subcutaneous implantable cardioverter-defibrillator in congenital heart disease.

Authors:  Linda Wang; Neeraj Javadekar; Ananya Rajagopalan; Nichole M Rogovoy; Kazi T Haq; Craig S Broberg; Larisa G Tereshchenko
Journal:  Heart Rhythm       Date:  2020-05       Impact factor: 6.343

Review 2.  Narrative review of: risk stratification and implantable cardioverter-defibrillator therapy in adults with congenital heart disease.

Authors:  Julia Köbe; Kevin Willy; Lars Eckardt; Helmut Baumgartner; Kristina Wasmer
Journal:  Cardiovasc Diagn Ther       Date:  2021-04

3.  Influence of subcutaneous implantable defibrillators on cardiovascular magnetic resonance image quality in pediatric patients.

Authors:  Sharib Gaffar; Anthony C McCanta; Pierangelo Renella
Journal:  HeartRhythm Case Rep       Date:  2022-04-26

4.  Eligibility for subcutaneous implantable cardioverter-defibrillator in adults with congenital heart disease.

Authors:  Christos Zormpas; Ann Sophie Silber-Peest; Jörg Eiringhaus; Henrike A K Hillmann; Stephan Hohmann; Johanna Müller-Leisse; Mechthild Westhoff-Bleck; Christian Veltmann; David Duncker
Journal:  ESC Heart Fail       Date:  2021-02-03

5.  Usefulness of the MADIT-ICD Benefit Score in a Large Mixed Patient Cohort of Primary Prevention of Sudden Cardiac Death.

Authors:  Kevin Willy; Julia Köbe; Florian Reinke; Benjamin Rath; Christian Ellermann; Julian Wolfes; Felix K Wegner; Patrick R Leitz; Philipp S Lange; Lars Eckardt; Gerrit Frommeyer
Journal:  J Pers Med       Date:  2022-07-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.